AARD Cash-Secured Put Strategy
AARD (Aardvark Therapeutics, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy.
AARD (Aardvark Therapeutics, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $143.8M, a beta of 3.81 versus the broader market, a 52-week range of 3.35-17.94, average daily share volume of 238K, a public-listing history dating back to 2025, approximately 40 full-time employees. These structural characteristics shape how AARD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 3.81 indicates AARD has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a cash-secured put on AARD?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
AARD snapshot
As of August 14, 2026, spot at $6.53, ATM IV 191.70%, IV rank 38.20%, expected move 54.96%. The cash-secured put on AARD below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this cash-secured put structure on AARD specifically: AARD IV at 191.70% is mid-range versus its 1-year history, so the credit collected on a AARD cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 54.96% (roughly $3.59 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AARD expiries trade a higher absolute premium for lower per-day decay. Position sizing on AARD should anchor to the underlying notional of $6.53 per share and to the trader's directional view on AARD stock.
AARD cash-secured put setup
The AARD cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AARD at $6.53 on that close, the first option leg uses a $6.20 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AARD chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AARD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $6.20 | N/A |
AARD cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
AARD cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on AARD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on AARD
Cash-secured puts on AARD earn premium while a trader waits to acquire AARD stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning AARD.
AARD thesis for this cash-secured put
The market-implied 1-standard-deviation range for AARD extends from approximately $2.94 on the downside to $10.12 on the upside. A AARD cash-secured put lets a trader earn premium while waiting to acquire AARD at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current AARD IV rank near 38.20% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on AARD should anchor more to the directional view and the expected-move geometry. As a Healthcare name, AARD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AARD-specific events.
AARD cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AARD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AARD alongside the broader basket even when AARD-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on AARD carry tail risk when realized volatility exceeds the implied move; review historical AARD earnings reactions and macro stress periods before sizing. Always rebuild the position from current AARD chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on AARD?
- A cash-secured put on AARD is the cash-secured put strategy applied to AARD (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With AARD stock at $6.53 on the most recent close, the strikes shown on this page are snapped to the nearest listed AARD chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are AARD cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the AARD cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 191.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AARD cash-secured put?
- The breakeven for the AARD cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The AARD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 54.96%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on AARD?
- Cash-secured puts on AARD earn premium while a trader waits to acquire AARD stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning AARD.
- How does current AARD implied volatility affect this cash-secured put?
- AARD ATM IV is at 191.70% with IV rank near 38.20%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.